The content on this site is intended for healthcare professionals only
At a press conference at SABCS 2014, Prof Hurvitz discusses the results of phase III Breast Cancer Trials of Oral Everolimus-1 (BOLERO-1) study.
This was a multicentre trial examining the effects of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2 advanced breast cancer.
Read the news story or watch the interview for more.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Highlights and analysis
ESMO 2024: Latest in EGFR mutated NSCLC
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
